AZmed is a French medical-imaging AI company founded in 2018 by CEO Julien Vidal, CTO Alexandre Attia, and Chief Medical Officer Dr. Elie Zerbib-Attal. It was the first French company to commercialize AI-powered radiology software, and its Rayvolve AI Suite now runs in more than 1,000 healthcare facilities across 40 countries.
Rayvolve's AZtrauma module holds FDA clearance for detecting fractures, joint effusions, and dislocations on adult and pediatric X-rays, making it the only FDA-cleared AI solution covering all three pathologies in the US as of its latest clearance. A companion module, AZchest, carries separate FDA clearance for flagging lung nodules and triaging pneumothorax and pleural effusion on chest X-rays, backed by a 2026 validation study covering 258,373 X-rays from 100 centers across 26 countries.
AZmed sells to hospitals, radiology groups, and emergency departments rather than individual clinicians. There is no public price list; facilities book a demo through the company's site, which matches the enterprise medical-device sales process common in this category.
